Status and phase
Conditions
Treatments
About
This is an open-label, single-arm, multiple ascending dose Phase I study to assess the dose- and concentration-dependent displacement of [18F]MNI-659 [a PET tracer targeting phosphodiesterase 10 (PDE10)] by EVP-6308.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
• Healthy male or female volunteers, 18 to 50 years of age
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
14 participants in 4 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal